Transcend Capital Advisors LLC Sells 19,729 Shares of AstraZeneca PLC (NASDAQ:AZN)

Transcend Capital Advisors LLC trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 27.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 52,891 shares of the company’s stock after selling 19,729 shares during the quarter. Transcend Capital Advisors LLC’s holdings in AstraZeneca were worth $3,887,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of AZN. Cibc World Markets Corp boosted its holdings in AstraZeneca by 1.1% in the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock worth $845,000 after buying an additional 142 shares during the period. CoreCap Advisors LLC boosted its holdings in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after buying an additional 155 shares during the period. Spinnaker Investment Group LLC boosted its holdings in shares of AstraZeneca by 3.1% during the 1st quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company’s stock valued at $423,000 after purchasing an additional 174 shares during the last quarter. Tiller Private Wealth Inc. boosted its holdings in shares of AstraZeneca by 5.7% during the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company’s stock valued at $219,000 after purchasing an additional 181 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its holdings in shares of AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after purchasing an additional 189 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Up 0.6%

AZN opened at $70.07 on Friday. The firm has a 50-day simple moving average of $70.55 and a two-hundred day simple moving average of $70.46. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $217.31 billion, a PE ratio of 28.14, a price-to-earnings-growth ratio of 1.28 and a beta of 0.38. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.06 EPS. Analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.